|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1995-10-3
|
|
pubmed:abstractText |
There are no large studies evaluating patients with erythrodermic mycosis fungoides and Sézary syndrome to determine the important prognostic factors that may influence survival. This is important since new treatment modalities have been proposed as superior to existing primary therapies. We performed a retrospective cohort study of 106 patients with erythrodermic mycosis fungoides and Sézary syndrome, followed up in the Stanford (Calif) Mycosis Fungoides Clinic, to define the important prognostic factors in this group.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
131
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1003-8
|
|
pubmed:dateRevised |
2008-3-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7661601-Adult,
pubmed-meshheading:7661601-Aged,
pubmed-meshheading:7661601-Cohort Studies,
pubmed-meshheading:7661601-Female,
pubmed-meshheading:7661601-Humans,
pubmed-meshheading:7661601-Lymphatic Metastasis,
pubmed-meshheading:7661601-Male,
pubmed-meshheading:7661601-Middle Aged,
pubmed-meshheading:7661601-Multivariate Analysis,
pubmed-meshheading:7661601-Mycosis Fungoides,
pubmed-meshheading:7661601-Prognosis,
pubmed-meshheading:7661601-Retrospective Studies,
pubmed-meshheading:7661601-Sezary Syndrome,
pubmed-meshheading:7661601-Skin Neoplasms,
pubmed-meshheading:7661601-Survival Rate
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
|
|
pubmed:affiliation |
Department of Dermatology, Stanford (Calif) University School of Medicine, USA.
|
|
pubmed:publicationType |
Journal Article
|
